Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease

Centre Hospitalier Universitaire de Besancon108 enrolled

Overview

Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

108

Conditions

Rheumatic Diseases Mood Disorders

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥18 ; ≤ 80) * Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria * Signature of informed consent * Affiliation to a French social security or receiving such a scheme Exclusion Criteria: * Patient having previously received anti-TNFα treatment * Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment * Subjects with limited legal capacity. * Subjects judged by the investigator to be unlikely to comply with study procedures * Subjects with no social security coverage. * Pregnant women. * Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.

Outcomes

Primary Outcomes

Severity of depressive symptoms

Score achieved on the validated self-report questionnaire (QIDS SR16) evaluating the severity of depressive symptoms

Time frame: 1 month after initiation of anti-TNFa therapy

Secondary Outcomes

Evaluation of disease activity

Evaluation with CPDAI (Composite Psoriatic Disease Activity Index) (minimum value: 0; maximum value: 15; increases with the activity of the disease)